U.S patent for Tryton Side Branch Stent System

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that a U.S. patent has been awarded for the company’s Tryton Side Branch Stent™ System.

The Tryton Side Branch Stent offers a dedicated strategy for treating atherosclerotic lesions at a bifurcation. These lesions have presented a challenge for cardiologists since the earliest days of angioplasty. Current approaches to treating these bifurcation lesions have limitations, most often neglecting the side branch. In cases where the side branch is treated it is often left unstented, leaving it vulnerable to higher rates of restenosis, the re-narrowing of a treated blood vessel.

“We’re very pleased that a United States patent has been awarded to Tryton Medical for the unique Tryton Side Branch Stent System, which is treating some of the most challenging interventional cases in cardiovascular disease,” said J. Greg Davis, president and CEO of Tryton Medical.

“This patent represents an important milestone for the company and our investors and is one of a family of patents currently under review at the Patent Office,” added Chief Technical Officer H. Richard Davis.

http://www.trytonmedical.com/